Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pharma Mar

- PMLiVE

Gilead boosts liver disease pipeline with $1.2bn acquisition

Also has combination HIV therapy Descovy approved by FDA

- PMLiVE

Pfizer’s PCSK9 inhibitor clears another phase III trial

Bococizumab will compete with Praluent and Repatha if it reaches the market

- PMLiVE

J&J drops NGF blocker fulranumab

Says decision to return rights to Amgen based on “strategic portfolio prioritisation”

- PMLiVE

GSK gene therapy tops CHMP recommendations

ADA-SCID treatment Strimvelis set for European approval

- PMLiVE

Amgen and UCB’s romosozumab hits goals in male osteoporosis

Firms will discuss data with regulators before planning a new male licence application

- PMLiVE

First round to Amgen in PCSK9 patent battle with Sanofi

US court concludes Praluent has infringed rival cholesterol drug Repatha

Gilead Sciences

Gilead wins US approval for second TAF-based HIV drug

FDA gives Odefsey the green light

Bristol Myers Squibb logo

Opdivo backed for two new uses by CHMP

Recommended for additional European approvals in kidney cancer and NSCLC

- PMLiVE

ViiV and Janssen take long-acting HIV regimen into phase III

Cabotegravir and rilpivirine injectable-therapy tipped as future blockbuster

- PMLiVE

Amgen says romosozumab on track for 2016 filing

Reports ‘significant’ reduction of fractures in post-menopausal osteoporosis patients

- PMLiVE

Amgen’s roll-out of myeloma drug Kyprolis reaches UK

Company hopes to gain NICE approval later this year

EU flag

Sandoz files for approval of Neulasta biosimilar in Europe

Amgen facing increasing competition in global biosimilar market

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links